In recent years, Global Bridges at Mayo Clinic and Pfizer Global Medical Grants have supported independent projects focused on raising awareness and closing knowledge gaps to reduce the time it takes for patients to be correctly diagnosed and make treatment more accessible, while supporting the development of a global network of TTR amyloidosis experts. Expanding the community of practice will help decrease the distance patients need to travel to be diagnosed, although valuable guidance may still be obtained from experienced centers further from home. This RFP is a continuation of this program.

For all independent quality improvement grants, the grant requester (and ultimately the grantee) is responsible for the design, implementation, and conduct of the independent initiative supported by the grant. Pfizer must not be involved in any aspect of project development, nor the conduct or monitoring of the quality improvement program.

Date RFP Issued: March 18, 2024

Geographic Scope: Global (excluding United States)

Clinical Area: TTR Amyloidosis

Link to full RFP: Raising Awareness and Promoting Timely Diagnosis of TTR Amyloidosis

Application Due Date: May 2, 2024

Specific Area of Interest: In order to increase the capacity of the health care system to provide more timely diagnosis and appropriate treatment to TTR amyloidosis sufferers in any organ, we are interested in receiving proposals that:

Reduce the time to correct diagnosis, among a broad audience of health care professionals, including increasing coordination across specialties; AND
Build on evidence and international best practice; AND
Include a robust and well-defined plan for evaluation and dissemination; AND
Support the development of a global network of health care professionals capable of diagnosing and treating TTR amyloidosis, AND
Support the development of a global network of TTR amyloidosis experts
Include a plan to sustain the project beyond the period of funding